GYRE · Gyre Therapeutics, Inc.
$6.87
-0.18 (-2.49%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$785.03M
Shares
111.51M
Volume · Oct 8
33.35K
Avg daily vol (3M)
105.74K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.04
Open$7.03
Day$6.99–7.15
52W close$5.56–8.87
Avg vol 30d163K
Short int1.7M · 1.6% float · 19.2d
Short vol73%
Last earningsNov 12, 2021
DataJan 2020–Oct 2026
Filing10-Q · Aug 7
Up next
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$116.42M
Trailing 12 months
Net income (TTM)
−$25.67M
Trailing 12 months
Revenue growth YoY
-2.1%
Year over year
Operating margin
-10.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.8%
Year over year · more shares
Price change (1Y)
-3.5%
Trailing year
Short interest
1.6%
Latest settlement · 19.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+4%
above
RSI (14)
49
neutral
MACD trend
Negative
52-week position
45%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
−11%
trailing
YTD return
0%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Flat
2 of 60 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.55% of float · ▲ +1.2% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 2-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
−92%
Y/Y
Gross margin
37045%
expanding
EPS growth
−60%
Y/Y
Free cash flow
$-180.0K
Balance sheet
$1.7M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 7, 2026
Revenue
· Full year 2026
Initiated
$100.5M – $111M
prior FY $116.59M
midpoint −9.3% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+4%
Bullish
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
45%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Flat
2 of 60 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.55% of float · ▲ +1.2% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $7 · 45%
Range high $9
vs 200-day avg -1%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Adjusted Net (Loss) Income non-GAAP | $12.2M | the three months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GYRE
this stock
Gyre Therapeutics, Inc.
|
$785.03M | -0.3% | -92.4% | — | 1.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.5% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.44B | +566.3% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.40B | -3.9% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GYRE | -4.0% | +1.3% | -10.9% | -4.0% | -0.3% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | -5.9% | -0.7% | -21.7% | -5.9% | -14.3% |